AC
KZIA

Armistice Capital’s Kazia Therapeutics KZIA Stock Holding History

Armistice Capital’s Portfolio KZIA Stock Details KZIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-49,511
Closed -$1.09M – 377
2023
Q4 		$1.09M Buy
+49,511
New +$1.45M 0.01% 174

Other funds holding KZIA

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
GSC
Ground Swell Capital Folly Beach, South Carolina $92.6M AUM 41.64% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
AF
Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $2.19B AUM 21.28% 1-Year Est. Return

Armistice Capital's KZIA Position: Q1 2024 in Review

Armistice Capital sold out of Kazia Therapeutics (KZIA) in Q1 2024, closing a stake of 49,511 shares — an estimated $1.09M sold.

Armistice Capital first reported a position in KZIA in Q4 2023 and held it in 1 quarter. The position peaked at $1.09M in Q4 2023. 9 funds tracked by Wall St. Rank hold KZIA as of Q1 2024.

  • Armistice Capital reported no remaining Kazia Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Armistice Capital sold 49,511 Kazia Therapeutics shares in Q1 2024, an estimated $1.09M.
  • Armistice Capital first reported a position in Kazia Therapeutics in Q4 2023 and held it in 1 quarter.
  • Armistice Capital's Kazia Therapeutics position peaked at $1.09M in Q4 2023.
  • 9 funds tracked by Wall St. Rank held Kazia Therapeutics as of Q1 2024.

Based on Armistice Capital's 13F filing for Q1 2024, filed 15 May 2024.